Get the Stockscreener App
12.78
0.12%
-0.015
After Hours:
12.78
0.005
+0.04%
Angiodynamic Inc stock is traded at $12.78, with a volume of 436.46K.
It is down -0.12% in the last 24 hours and up +5.58% over the past month.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
See More
Previous Close:
$12.79
Open:
$12.79
24h Volume:
436.46K
Relative Volume:
1.22
Market Cap:
$527.85M
Revenue:
$313.73M
Net Income/Loss:
$-31.39M
P/E Ratio:
-16.82
EPS:
-0.7597
Net Cash Flow:
$-3.53M
1W Performance:
-1.58%
1M Performance:
+5.58%
6M Performance:
+26.86%
1Y Performance:
+37.07%
1-Day Range:
$12.71
$13.01
1-Week Range:
$12.55
$13.26
52-Week Range:
$8.36
$13.99
Angiodynamic Inc Stock (ANGO) Company Profile
Name
Angiodynamic Inc
Sector
Industry
Phone
(518) 798-1215
Address
14 PLAZA DRIVE, LATHAM
Compare ANGO vs ISRG, BDX, MDLN, ALC, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANGO
Angiodynamic Inc
|
12.78 | 528.47M | 313.73M | -31.39M | -3.53M | -0.7597 |
ISRG
Intuitive Surgical Inc
|
407.12 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
153.83 | 41.87B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
40.58 | 34.70B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
69.00 | 33.07B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
198.50 | 29.57B | 5.54B | 1.52B | 1.74B | 10.37 |
Angiodynamic Inc Stock (ANGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Initiated | Lake Street | Buy |
| Apr-05-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-25-23 | Initiated | H.C. Wainwright | Buy |
| Apr-17-23 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-15-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-20-21 | Initiated | Oppenheimer | Perform |
| Nov-25-20 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Apr-08-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-01-19 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Apr-03-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-18 | Downgrade | Craig Hallum | Buy → Hold |
| Apr-07-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Mar-30-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
| Feb-08-17 | Initiated | Barclays | Equal Weight |
| Nov-04-16 | Initiated | Cantor Fitzgerald | Buy |
| Apr-08-16 | Resumed | Piper Jaffray | Neutral |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Nov-10-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-24-15 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jun-19-14 | Upgrade | Canaccord Genuity | Hold → Buy |
| Oct-09-12 | Reiterated | Canaccord Genuity | Hold |
| Jun-25-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-15-11 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-15-11 | Upgrade | Stifel Nicolaus | Hold → Buy |
| Jun-14-11 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-08-10 | Reiterated | Wedbush | Neutral |
View All
Angiodynamic Inc Stock (ANGO) Latest News
AngioDynamics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ANGOAngiodynamic Inc Latest SEC Filings - Finviz
Price to sales forward of AngioDynamics, Inc. – NASDAQ:ANGO - TradingView
Price to sales forward of AngioDynamics, Inc. – LS:A0B9A5 - TradingView
Press Release: AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026 - Moomoo
AngioDynamics sets July 14 call for fiscal 2026 results - Stock Titan
AngioDynamics, Inc.(NasdaqGS: ANGO) added to Russell 2000 Value-Defensive Index - marketscreener.com
AngioDynamics, Inc. Actuals & Estimates (NASDAQ:ANGO) - TradingView
ANGO Forecast — Price Target — Prediction for 2027 - TradingView
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now - TradingView
AngioDynamics Inc (ANGO) Valuation: PE, PB & Fair Value Analysis - TradingKey
AngioDynamics Inc (ANGO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AngioDynamics wins FDA okay to test NanoKnife in BPH patients - Stock Titan
AngioDynamics Inc (ANGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AngioDynamics Inc (ANGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AngioDynamics Inc (ANGO) Institutional Confidence - TradingKey
AngioDynamics Inc (ANGO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026Slideshow - Seeking Alpha
ANGO News | ANGIODYNAMICS INC (NASDAQ:ANGO) - ChartMill
Port Catheter Thrombosis Lawsuit Claims Defective AngioDynamics Xcela Device Caused Injury - AboutLawsuits.com
ANGO Technical Analysis & Stock Price Forecast - Intellectia AI
ANGO Stock Price, Quote & Chart | ANGIODYNAMICS INC (NASDAQ:ANGO) - ChartMill
Webcast set for AngioDynamics talk at Goldman Sachs health event - Stock Titan
Reasons to Add AngioDynamics Stock to Your Portfolio for Now - Yahoo Finance
Point72 (ANGO) reports 3.18M shares, 7.7% stake via Point72 Associates - Stock Titan
Prostate cancer trial sees 0 new failures with NanoKnife at 2 years - Stock Titan
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet - Yahoo Finance
AngioDynamics alleges patent infringement by E2 over clot removal technology - MassDevice
[8-K] ANGIODYNAMICS INC Reports Material Event - Stock Titan
Fair Value Assessment | AngioDynamics Inc. posts 117.8% EPS surprise beating loss estimatesEarnings Risk - Cổng thông tin điện tử tỉnh Tây Ninh
AngioDynamics files patent lawsuit against Endovascular Engineering - Investing.com
ANGO (AngioDynamics Inc.) notches massive Q1 2026 EPS beat, but shares fall 1.24 percent on slight year over year revenue decline.Social Trade Signals - Xã Thanh Hà
AngioDynamics (ANGO) Upgraded to Buy: Here's Why - Yahoo Finance
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down - TradingView
AngioDynamics Growing, But With More Noise Than The Street Likes (NASDAQ:ANGO) - Seeking Alpha
AngioDynamics Inc. Q3 2026 Financial Results: Revenue, Net Loss, and Key Financial Statements Overview - Minichart
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2026 Earnings Call Transcript - Insider Monkey
AngioDynamics (NASDAQ: ANGO) Q3 2026 revenue up 9% while net loss grows - Stock Titan
AngioDynamics, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
AngioDynamics, Inc. 2026 Q3ResultsEarnings Call Presentation (NASDAQ:ANGO) 2026-04-02 - Seeking Alpha
AngioDynamics Inc (NASDAQ:ANGO) Beats Q3 Earnings Estimates and Raises Full-Year Guidance - ChartMill
ANGIODYNAMICS ($ANGO) Releases Q3 2026 Earnings | ANGO Stock News - Quiver Quantitative
AngioDynamics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
AngioDynamics investors can watch Needham conference webcast April 14 - Stock Titan
Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 18.0% - Defense World
AngioDynamics, Inc. (NASDAQ:ANGO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
AngioDynamics, Inc. (ANGO) Investor Outlook: Unpacking A 71.55% Potential Upside - DirectorsTalk Interviews
Vanguard disaggregates holdings; reports 0 shares in AngioDynamics (ANGO) - Stock Titan
AngioDynamics, Inc. (ANGO) Stock Analysis: A Potential 81.88% Upside For Investors - DirectorsTalk Interviews
AngioDynamics schedules April 2 earnings call before market open - Stock Titan
Bard And AngioDynamics Resolve 11-Year Patent Dispute - Law360
Angiodynamic Inc Stock (ANGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Angiodynamic Inc Stock (ANGO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Trowbridge Stephen A | EVP and CFO |
Oct 13 '25 |
Buy |
11.16 |
890 |
9,932 |
256,629 |
| Clemmer James C | President and CEO |
Oct 09 '25 |
Buy |
11.15 |
10,000 |
111,500 |
882,529 |
0.22%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):